Altamira Therapeutics Ltd. (CYTO)
NASDAQ: CYTO · Real-Time Price · USD
0.440
0.00 (-0.02%)
Nov 20, 2024, 4:00 PM EST - Market closed
Altamira Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Selling, General & Admin | 3.21 | 3.12 | 3.4 | 3.67 | 2.63 | 3.95 | Upgrade
|
| Research & Development | 3.86 | 3.04 | 2.22 | 1.67 | 2.83 | 3.3 | Upgrade
|
| Other Operating Expenses | -0.23 | -0.24 | -0.01 | 0 | -0.18 | 0.01 | Upgrade
|
| Operating Expenses | 6.85 | 5.92 | 5.62 | 5.34 | 5.28 | 7.26 | Upgrade
|
| Operating Income | -6.85 | -5.92 | -5.62 | -5.34 | -5.28 | -7.26 | Upgrade
|
| Interest Expense | -0.58 | -1.03 | -0.9 | -0.01 | -0.14 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.31 | 0.3 | 0.11 | 0.03 | 0 | 0.02 | Upgrade
|
| Earnings From Equity Investments | -0.28 | -0.04 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.55 | -0.45 | -0.31 | 0.05 | -0.33 | -0.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.04 | -0.17 | 0.45 | 0.01 | -2.47 | 0.66 | Upgrade
|
| EBT Excluding Unusual Items | -7.91 | -7.3 | -6.26 | -5.28 | -8.22 | -6.83 | Upgrade
|
| Asset Writedown | - | - | -12.4 | -1.53 | - | - | Upgrade
|
| Other Unusual Items | 0 | 0.03 | - | - | - | - | Upgrade
|
| Pretax Income | -7.91 | -7.27 | -18.66 | -6.81 | -8.22 | -6.83 | Upgrade
|
| Income Tax Expense | - | - | -0.01 | -0.12 | -0.02 | -0.19 | Upgrade
|
| Earnings From Continuing Operations | -7.91 | -7.27 | -18.65 | -6.69 | -8.2 | -6.63 | Upgrade
|
| Earnings From Discontinued Operations | 5.21 | 3.4 | -7.88 | -10.37 | - | - | Upgrade
|
| Net Income | -2.7 | -3.87 | -26.53 | -17.06 | -8.2 | -6.63 | Upgrade
|
| Net Income to Common | -2.7 | -3.87 | -26.53 | -17.06 | -8.2 | -6.63 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | - | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | - | Upgrade
|
| Shares Change (YoY) | 1503.64% | 978.83% | 37.50% | 120.26% | - | - | Upgrade
|
| EPS (Basic) | -1.91 | -7.88 | -582.58 | -515.11 | -545.41 | - | Upgrade
|
| EPS (Diluted) | -1.91 | -7.88 | -582.58 | -515.11 | -545.41 | - | Upgrade
|
| Free Cash Flow | -7.58 | -11.51 | -8.68 | -13.67 | -4.84 | -8.46 | Upgrade
|
| Free Cash Flow Per Share | -5.35 | -23.43 | -190.69 | -412.87 | -322.15 | - | Upgrade
|
| EBITDA | - | - | -5.57 | -5.29 | -5.26 | -7.23 | Upgrade
|
| D&A For EBITDA | - | - | 0.05 | 0.05 | 0.02 | 0.03 | Upgrade
|
| EBIT | -6.85 | -5.92 | -5.62 | -5.34 | -5.28 | -7.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.